their mutation-specificity excludes up to 85% of KRAS-mutant cancers, including those with G12D, G12V, and G13D mutations. To address this gap, we developed RV-1521, a broad-spectrum mRNA vaccine ...

The Kirsten rat sarcoma viral oncogene homolog (KRAS) gene is mutated in over 90% of pancreatic adenocarcinoma (PDAC). These mutations are predominantly single-base missense variants, 98% of which are ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

They will also work on an inhibitor of KRAS G12C that could compete with sotorasib (BI 1823911) and an MEK inhibitor (BI 3011441), as well as a novel undisclosed bi-specific TRAILR2 agonist.

The KRAS G12D mutation occurs most commonly in pancreatic (37%), colorectal (12.5%), endometrial (8%), and non-small cell lung (5%) cancers. Currently, no therapies are approved by the U.S. Food ...

KRAS G12D represents 26% of all KRAS mutations, making it the most prevalent KRAS mutation in human cancers. The KRAS G12D mutation occurs most commonly in pancreatic (37%), colorectal (12.5%), ...

More information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR. Targeted small molecule ...

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in ...

Researchers at Hopkins have made strides in pancreatic cancer research, both in understanding age-related differences in ...

Expect to initiate a Phase 1/2a trial in the U.S. in advanced KRAS G12D mutant solid tumors in mid-2025 Initial safety and efficacy results from the trial of VS-7375 by partner GenFleet ...